Dr Paul C. Guest, Ph.D, is a scientific researcher/writer with 35 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and Alzheimer’s disease.

• 1. The Potential of ‘Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer’s Disease in African Americans.- 2. The Role of Biomarkers in Alzheimer’s Disease Drug Development.- 3. Mitochondrial Involvement in Mental Disorders; Energy Metabolism, Genetic and Environmental Factors.- 4. Lymphocytes, Platelets, Erythrocytes and Exosomes as Possible Biomarkers for Alzheimer's Disease Clinical Diagnosis.- 5. Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms.- 6. Neuroimaging Studies of Cognitive Function in Schizophrenia.- 7. The Role of Biomarkers in Psychiatry.- 8. Interactome Studies of Psychiatric Disorders.- 9. MicroRNAs in Major Depressive Disorder.- 10. Proteomic Markers for Depression.- 11. Advances in Biomarker Studies in Autism Spectrum Disorders.- 12. Proteomic Investigations of Autism Spectrum Disorder: Past Findings, Current Challenges and Future Prospects.- 13. Role of the Gut Microbiome in AutismSpectrum Disorders.- 14. Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia.- 15. Early Detection and Treatment of Patients with Alzheimer’s Disease: Future Perspectives.

Dr Paul C. Guest, Ph.D, is a scientific researcher/writer with 35 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and Alzheimer’s disease.

• 1. The Potential of ‘Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer’s Disease in African Americans.- 2. The Role of Biomarkers in Alzheimer’s Disease Drug Development.- 3. Mitochondrial Involvement in Mental Disorders; Energy Metabolism, Genetic and Environmental Factors.- 4. Lymphocytes, Platelets, Erythrocytes and Exosomes as Possible Biomarkers for Alzheimer's Disease Clinical Diagnosis.- 5. Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms.- 6. Neuroimaging Studies of Cognitive Function in Schizophrenia.- 7. The Role of Biomarkers in Psychiatry.- 8. Interactome Studies of Psychiatric Disorders.- 9. MicroRNAs in Major Depressive Disorder.- 10. Proteomic Markers for Depression.- 11. Advances in Biomarker Studies in Autism Spectrum Disorders.- 12. Proteomic Investigations of Autism Spectrum Disorder: Past Findings, Current Challenges and Future Prospects.- 13. Role of the Gut Microbiome in AutismSpectrum Disorders.- 14. Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia.- 15. Early Detection and Treatment of Patients with Alzheimer’s Disease: Future Perspectives.